drugset / Trial / NCT07517263
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NaSingle-groupOpen-labelTreatment
Summary
This open-label extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed the double-blind parent study (CTQJ230A12301).
Timeline
- Start
- 2026-05-11
- Primary completion
- 2030-01-09
- Completion
- 2030-01-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pelacarsen | Antisense oligonucleotide | 80 mg | Subcutaneous |
Indications
No indication recorded.